Navidea Biopharmaceuticals

Historical price data

Navidea Biopharmaceuticals' mission is to advance precision medicine by developing targeted diagnostics and therapies that identify undetected disease sites. Its core achievement is the Manocept platform, which led to the FDA-approved radiopharmaceutical Tc99m Tilmanocept (Lymphoseek®) for lymphatic mapping, the rights to which were sold to Cardinal Health in a deal worth up to $325 million. The company's strategy has been to leverage this platform across multiple inflammatory and oncologic indications, but its execution has been severely hampered by persistent financial instability, culminating in a Chapter 11 bankruptcy filing in October 2025, casting significant doubt on its future viability.

The Manocept platform is a carbohydrate-based molecular backbone engineered to target the CD206 receptor on macrophages, enabling the development of targeted diagnostic imaging agents and therapeutic conjugates for a range of diseases.

Navidea competes in the highly competitive and well-capitalized fields of radiopharmaceuticals and macrophage-targeting therapies against giants like Novartis and Bayer, as well as numerous agile biotechs. Its bankruptcy has eliminated its ability to compete on clinical development or financial resources, rendering its scientific differentiation moot in the market.